Keep pulling the thread on Oura Health.
Approximately 85% of all diseases treated in U.S. hospitals are age-related.
Oura Health is developing the capability to measure blood pressure with an accuracy within 5% of clinical-grade devices using its ring.
Retro Biosciences' molecule RTR-242, which is designed to restart the autophagy process in aged neurons, is most of the way through its first clinical trial.
Linkgevity has identified a first-in-class drug to target unregulated cell death (necrosis) and plans to take it into Phase 2 clinical trials with the UK's National Health Service.
An NIH-funded randomized controlled trial showed that compliant users of the free software at retainyourbrain.com reduced their Alzheimer's risk by 16 percentage points in 6 months through behavior change alone.
Kidney disease accounts for 24% of Medicare's annual budget.
Oura Health has collected over 30 billion hours of human physiological data across diverse demographics.
Most digital health tools and wearables are not considered "covered entities" under HIPAA, meaning users should have no expectation of privacy for their health data.
To date, no therapeutic has been approved by any major regulator for the specific indication of "aging."
The U.S. FDA has approved two clinical trials for "aging" as an indication, which function as basket trials for multiple age-related diseases.
Joe Betz-Lacroix predicts that within the next five years, Retro Biosciences will have one approved therapeutic on the market and a total of four therapeutics in human testing.
The current U.S. medical system is a "sick care system" because doctors are reimbursed for treating symptoms in sick people, not for preventing disease.